Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.
Citations
Citations to this article as recorded by
Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach Antonio Frolli, Guido Parvis, Martina Bullo, Selene Grano, Giovanni Fornari, Valentina Bonuomo, Daniela Cilloni, Carmen Fava Hematology Reports.2025; 17(6): 69. CrossRef
The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade International Journal of Clinical Pharmacy.2024; 46(2): 368. CrossRef
Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity Ege Arzuk Toxicology Letters.2024; 400: 71. CrossRef
Antioxidant-Based Preventive Effect of Phytochemicals on Anticancer Drug-Induced Hepatotoxicity Ji Eon Park, Chi-Hoon Ahn, Hyo-Jung Lee, Deok Yong Sim, Su Yeon Park, Bonglee Kim, Bum Sang Shim, Dae Young Lee, Sung-Hoon Kim Antioxidants & Redox Signaling.2023; 38(16-18): 1101. CrossRef